159 related articles for article (PubMed ID: 29575765)
1. Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.
Xia P; Cao J; Lv X; Wang L; Lv W; Hu J
Thorac Cancer; 2018 May; 9(5):656-661. PubMed ID: 29575765
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
3. Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Wang J; Chen J
BMC Cancer; 2019 Feb; 19(1):131. PubMed ID: 30736738
[TBL] [Abstract][Full Text] [Related]
4. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Liu Q; Wu L; Zhang S
Tumori; 2021 Dec; 107(6):NP5-NP10. PubMed ID: 33896242
[TBL] [Abstract][Full Text] [Related]
5. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Xu L; Qi Q; Zhang Y; Cui J; Liu R; Li Y
Lung Cancer; 2019 Jul; 133():23-31. PubMed ID: 31200823
[TBL] [Abstract][Full Text] [Related]
6. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K; Guo C; Li R
Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
[TBL] [Abstract][Full Text] [Related]
8. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
9. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y
Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Med; 2020 Jan; 9(1):12-18. PubMed ID: 31692291
[TBL] [Abstract][Full Text] [Related]
14. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
Wang Y; Li L; Han R; Jiao L; Zheng J; He Y
Lung Cancer; 2018 Apr; 118():105-110. PubMed ID: 29571987
[TBL] [Abstract][Full Text] [Related]
15. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Sci; 2020 Feb; 111(2):679-686. PubMed ID: 31828849
[TBL] [Abstract][Full Text] [Related]
16. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
[TBL] [Abstract][Full Text] [Related]
19. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
20. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]